Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products, claims Roots Analysis

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.

• A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
• A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
• Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.

To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this link

The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:

• Types of Primary Packaging Containers
• Ampoules
• Cartridges
• Syringes
• Vials

• Types of Biologics
• Peptides / proteins
• Antibodies
• Vaccines
• Cell therapies
• Gene therapies
• Viral products
• Oligonucleotides
• Others

• Company Size
• Small-sized
• Mid-sized
• Large / very large

• Scale of Operation
• Preclinical
• Clinical
• Commercial

• Key Therapeutic Areas
• Cancer
• Infectious diseases
• Autoimmune diseases
• Cardiovascular diseases
• Other indications

• Key Geographical Regions
• North America (US, Canada)
• Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
• Asia-Pacific (Japan, China, South Korea, India and Australia)

The Biologics Fill / Finish Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Advanced BioScience Laboratories (ABL)
• Albany Molecular Research (AMRI)
• Biocon
• BioPharma Solutions
• BioReliance
• Boehringer Ingelheim BioXcellence
• ChemPartner
• Emergent BioSolutions
• IDT Biologika
• Lonza
• LuinaBio
• Mycenax Biotech
• Patheon
• Recipharm
• Vetter Pharma
• WuXi Biologics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction
 

4. Competitive Landscape
 

5. Company Competitiveness Analysis
 

6. Biologics Fill / Finish Service Providers in North America: Company Profiles
 

7. Biologics Fill / Finish Service Providers in Europe: Company Profiles
 

8. Biologics Fill / Finish Service Providers in Asia-Pacific: Company Profiles
 

9. Partnerships and Collaborations
 

10. Recent Expansions
 

11. Capacity Analysis
 

12. Demand Analysis
 

13. Biologics Manufacturing and Fill / Finish: Key Performance Indicator Analysis
 

14. Market Sizing and Opportunity Analysis

15. Future Growth Opportunities

16. Case Study: Robotic Systems in Fill / Finish Operations

17. Case Study: Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]